The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.
Regeneron Pharmaceuticals, Inc. and Sanofi announced the voluntarily withdrawal of the supplemental biologics license application for cemiplimab-rwlc as a second-line treatment for patients with advanced cervical cancer whose disease progressed on or after chemotherapy.
The FDA has granted a fast track designation to CX-5461 (Pidnarulex) as a potential therapeutic option for patients with breast and ovarian cancers that harbor BRCA1/2, PALB2, or other homologous recombination deficiency mutations.
Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.
The Japanese Ministry of Health, Labour, and Welfare has approved the combination of pembrolizumab plus lenvatinib for use in patients with unresectable, advanced, or recurrent endometrial carcinoma that has progressed on chemotherapy.
Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.
Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.
Image-guided intensity-modulated radiotherapy caused less toxicity compared with three-dimensional conformal radiation therapy with no difference in disease outcomes in patients with cervical cancer undergoing postoperative radiation therapy.
Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.
Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.